Macera Therapeutics Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series A1

  • Investors
  • 8

Macera Therapeutics General Information

Description

Manufacturer of macrophage immunotherapy drugs designed to treat gastric cancer, liver cancer, prostate cancer, and other solid tumors and autoimmune diseases. The company's drugs have integrated and non-integrated molecular editing and manipulation systems, iPSC-derived immune cell differentiation systems, ligand-receptor and other information flow recognition and conduction technology platforms, enabling doctors to kill tumor cells and regulate autoimmune cell cloning.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 745, Block A, Phase I, Zhongdan Ecological Life Science Industrial Park
  • Number 3-1 Xinjinhu Road, Jiangbei New District
  • Nanjing, Jiangsu 210031
  • China
+86 159
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Room 745, Block A, Phase I, Zhongdan Ecological Life Science Industrial Park
  • Number 3-1 Xinjinhu Road, Jiangbei New District
  • Nanjing, Jiangsu 210031
  • China
+86 159

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Macera Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series A1) 17-May-2026 Completed Generating Revenue
3. Early Stage VC (Series A) 23-Jun-2025 Completed Generating Revenue
2. Seed Round 03-Jan-2023 Completed Startup
1. Seed Round 07-Dec-2022 Completed Startup
To view Macera Therapeutics’s complete valuation and funding history, request access »

Macera Therapeutics Patents

Macera Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026223521-A1 Cytokine combination for preventing and/or treating fibrosis Pending 22-Apr-2025
WO-2026114326-A1 Intracellular signaling domain of chimeric antigen receptor and use thereof Pending 28-Nov-2024
WO-2026016944-A1 Adenovirus vector and use thereof Pending 15-Jul-2024
WO-2024093147-A1 Antibody specifically binding to v5 exon of cd44, and use thereof Inactive 31-Oct-2022 C07K16/2884

Macera Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Dingxin Capital Venture Capital Minority
Fan Zhuo Capital Corporate Venture Capital Minority
Zijin Hi-Tech Venture Capital Venture Capital Minority
Nanjing Innovation Capital Group Venture Capital Minority
CDH Investments PE/Buyout Minority
You’re viewing 5 of 8 investors. Get the full list »

Macera Therapeutics FAQs

  • When was Macera Therapeutics founded?

    Macera Therapeutics was founded in 2022.

  • Where is Macera Therapeutics headquartered?

    Macera Therapeutics is headquartered in Nanjing, China.

  • What industry is Macera Therapeutics in?

    Macera Therapeutics’s primary industry is Drug Discovery.

  • Is Macera Therapeutics a private or public company?

    Macera Therapeutics is a Private company.

  • What is Macera Therapeutics’s current revenue?

    The current revenue for Macera Therapeutics is .

  • Who are Macera Therapeutics’s investors?

    Dingxin Capital, Fan Zhuo Capital, Zijin Hi-Tech Venture Capital, Nanjing Innovation Capital Group, and CDH Investments are 5 of 8 investors who have invested in Macera Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process